UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~June~~ August 123, 2006

Interpharm Holdings, Inc.

(Exact name of Registrant as specified in charter)

Delaware	0-22710	13-3673965
(State or other jurisdic-	(Commission	(IRS Employer
tion of incorporation)	File Number)	Identification No.)


75 Adams Avenue, Hauppauge, New York		11788
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (631) 952- 0214

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8 5.~~01 Other Events~~02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On ~~June~~August 123, 2006, ~~Ray~~the ~~Vuono~~Board ~~(“Vuono”)~~of ~~commenced~~Directors anelected ~~action~~Joan ~~against~~Neuscheler ~~Interpharm~~to ~~Holdings Inc.~~fill ~~(the~~a ~~“Company”)~~vacancy in the Board ~~Supreme Court~~ of ~~the~~Directors. ~~State~~The Certificate of ~~New York~~Designations, ~~County~~Preferences and Rights of ~~Suffolk~~the ~~(Index~~Series ~~No.~~B-1 ~~13985/06).~~Convertible ~~Vuono’s~~Preferred ~~complaint~~Stock ~~against~~of Interpharm ~~alleges~~Holdings, Inc. (the ~~among~~“Series ~~other~~B-1 ~~things,~~Stock”) provides that ~~Vuono~~so islong ~~entitled~~as toTullis-Dickerson ~~receive~~Capital ~~additional~~Focus ~~compensation~~III, ~~as a~~L.P. (“~~finder~~TD III”~~under~~) or an ~~agreement~~affiliate ~~dated~~of ~~July~~TD 1,III ~~2002~~continues ~~between~~to ~~Vuono~~hold ~~and~~at ~~the~~least ~~Company~~twenty five percent (~~then~~25%) ~~known~~of asthe ~~Atec~~cumulative ~~Group,~~aggregate ~~Inc.)~~number ~~with~~of ~~respect~~shares toof aSeries ~~reverse~~B-1 ~~merger transaction~~Stock ~~consummated~~issued byto ~~the~~TD ~~Company~~III inon ~~May~~the ~~2003.~~initial ~~Vuono~~issuance ~~also~~date ~~alleges~~of ~~that~~the heSeries isB-1 ~~entitled~~Stock, TD III shall be entitled to ~~additional~~elect ~~compensation~~one ~~under~~director to the ~~agreement~~Board inof ~~respect~~Directors of ~~a $41.5 million~~the ~~credit~~Company. ~~facility~~On ~~from~~August ~~Wells~~23, ~~Fargo~~2006 ~~Business~~TD ~~Credit,~~III ~~Inc~~designated Ms. ~~obtained~~Neuscheler byfor ~~the~~election ~~Company~~as ina director ~~February~~of ~~2006 and~~ the ~~sale~~Company. ~~for~~The ~~$10~~Company ~~million~~does ofnot ~~shares~~know ofat athis ~~new~~time ~~series~~whether ofMs. ~~convertible~~Neuscheler ~~preferred~~will ~~stock~~be ~~and~~appointed ~~warrants~~as toa ~~purchase~~member ~~common~~of ~~stock~~any committee of the ~~Company~~ ~~consummated by the Company with Tullis-Dickerson Capital Focus III, L~~Board.~~P. in~~ ~~May~~Richard ~~2006~~J. ~~The~~Miller, ~~total~~the ~~amount~~original designee of ~~damages~~TD ~~sought~~III, byhas ~~Vuono~~agreed into ~~the~~remain ~~action~~as isa ~~in excess~~director of ~~$10~~ ~~million~~the Company.

~~The~~Ms. ~~Company~~Neuscheler, ~~believes~~age ~~that~~47, ~~Vuono~~has 17 years of experience in private equity investing as an officer of Tullis-Dickerson & Co., Inc. (“TD”), a health care-focused venture capital firm. Since July 1998, Ms. Neuscheler has been the President of TD. Ms. Neuscheler’s ~~claims~~previous ~~are~~experience includes ~~without~~three ~~merit~~years ~~and~~in ~~the~~public ~~Company~~accounting ~~intends~~with Arthur Andersen and five years toexperience ~~timely~~as a ~~file~~senior ~~appropriate~~officer ~~pleadings~~in ora ~~motions~~reinsurance ~~seeking~~brokerage firm. Ms. Neuscheler is a ~~dismissal~~Director of ~~the~~Adams Respiratory Therapeutics, ~~complaint~~Inc. (NasdaqGS: ~~with~~ARXT), ~~prejudice~~a specialty pharmaceutical company, and a number of privately held companies. She received her B.B.A. and her M.B.A. from Pace University.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERPHARM HOLDINGS, INC.
June 28, 2006	By:	/s/ George Aronson
August 25, 2006	By:/s/ George Aronson
		George Aronson Chief Financial Officer
	George Aronson
	Chief Financial Officer

Filing Compare · INTERPHARM HOLDINGS INC